TNFRSF9 and neoplasm: In brief, adoptively transferred T-cells were first infused and were found to upregulate 4-1BB expression only at the site of tumor, thus yielding a therapeutic window for 4-1BB agonist treatment 3 days after lymphocyte infusion [206].